JAK inhibitors for hair loss receive US patents

The US patent office has issued two patents for janus kinase inhibitors for hair loss, according to a press release from Aclaris Therapeutics.

One of the patents includes coverage for tofacitinib, baricitinib (Olumiant, Incyte & Lilly), ruxolitinib (Jakafi, Incyte) and decernotinib (KareBay Biochem) as therapeutic options for androgenetic alopecia, or pattern hair loss. There are 22 claims in this patent, according to the statement.

The other patent focuses exclusively on baricitinib as an agent for both inducing hair growth and managing a number of hair loss conditions including alopecia areata and androgenetic alopecia. There are 10 claims included in this patent.

Both patents expire in November 2031.

The Trustees of Columbia University in the City of New York own both patents, which have been licensed to Aclaris. – by Rob Volansky

 

 

The US patent office has issued two patents for janus kinase inhibitors for hair loss, according to a press release from Aclaris Therapeutics.

One of the patents includes coverage for tofacitinib, baricitinib (Olumiant, Incyte & Lilly), ruxolitinib (Jakafi, Incyte) and decernotinib (KareBay Biochem) as therapeutic options for androgenetic alopecia, or pattern hair loss. There are 22 claims in this patent, according to the statement.

The other patent focuses exclusively on baricitinib as an agent for both inducing hair growth and managing a number of hair loss conditions including alopecia areata and androgenetic alopecia. There are 10 claims included in this patent.

Both patents expire in November 2031.

The Trustees of Columbia University in the City of New York own both patents, which have been licensed to Aclaris. – by Rob Volansky